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ABSTRACT
Objectives To compare custom- made insoles to sham 
insoles and general practice (GP)- led usual care in terms 
of pain at rest and during activity at 12 weeks follow- up 
in individuals with plantar heel pain.
Methods In this randomised clinical trial 185 patients 
aged 18 to 65 years, with a clinical diagnosis of plantar 
heel pain for at least 2 weeks, but no longer than 2 years 
were recruited. Patients were randomly allocated into 
three groups: (1) GP- led treatment, plus an information 
booklet with exercises (usual care; n=46), (2) referral to 
a podiatrist for treatment with a custom- made insole 
plus an information booklet with exercises (custom- 
made insole; n=70) and (3) referral to a podiatrist 
and treatment with a sham insole plus an information 
booklet with exercises (sham insole; n=69). As well as 
the primary outcome of pain severity (11- point Numerical 
Rating Scale) we used the Foot Function Index (0 to 100) 
as a secondary outcome.
Results Of 185 randomised participants, 176 
completed the 12- week follow- up. There was no 
difference in pain or function between the insole and 
the sham groups at 12 weeks. Participants in the GP- led 
usual care group reported less pain during activity at 
12 weeks, (mean difference (MD) 0.94, 95% CI 0.23 
to 1.65), less first step pain (MD 1.48, 95% CI 0.65 to 
2.31), better function (MD 7.37, 95% CI 1.27 to 13.46) 
and higher recovery rates (RR 0.48, 95% CI 0.24 to 0.96) 
compared with participants in the custom insole group.
Conclusions Referral to a podiatrist for a custom- made 
insole does not lead to a better outcome compared to 
sham insoles or compared to GP- led usual care.
Trial registration number NTR5346.
INTRODUCTION
Plantar heel pain, also known as plantar fasciitis 
or fasciopathy, is a common cause of foot pain. 
Plantar heel pain accounts for an estimated 8% to 
15% of all foot complaints requiring medical care 
in adults.1 2 Plantar heel pain typically affects highly 
physically active people, such as running athletes, 
but is also common in middle- aged (40 to 60 years) 
women with high body mass index (BMI).3–6 The 
incidence of plantar heel pain in Dutch general 
practice is approximately 3.8 per 1000 patient- 
years.7 The clinical course of plantar heel pain is 
considered favourable with remission after 12 to 
24 months in 60% to 80% of patients.8 9 However, 
given the effect of the complaints on every day and 
sports activities, the burden on patients is high.10 
There is a need for effective treatment options, that 
can speed up recovery and limit impact.
Plantar heel pain can be managed by a range 
of different treatments in clinical practice and 
orthoses, such as in- shoe foot insoles are commonly 
applied by clinicians.11 Two systematic reviews 
found conflicting evidence for the effectiveness of 
orthoses on pain in plantar heel pain.12 13 Whittaker 
et al found a small, but statistically significant, bene-
ficial effect of insoles on heel pain at 7 to 12 weeks 
when compared with sham.12 In contrast, a more 
recent systematic review concluded that insoles are 
not superior to sham in reducing pain in individ-
uals with plantar heel pain.13 Of the three trials 
comparing custom- made insoles to sham, none 
were performed in a primary care setting.13 Addi-
tionally, no study has compared orthoses to usual 
care, despite custom- made insoles being the most 
frequent applied interventions for plantar heel pain 
in general practice.7 The added effect of insoles 
to sham is unclear and to usual care is unknown, 
making it impossible to know if referral for custom- 
made insoles is an appropriate option for patients 
who consult general practice.
We conducted a randomised clinical trial with 
a pragmatic design that compared custom- made 
insoles with sham insoles, as well as general prac-
tice (GP)- led usual care. The hypothesis was that 
custom- made insoles would be better than sham 
insoles and GP- led usual care at 12 weeks follow- up 
in terms of pain at rest and during activity.
METHODS
Trial design
The study was performed according to the 
published protocol.14 Briefly, we performed a prag-
matic three- armed participant- blinded and assessor- 
blinded randomised controlled trial in primary 
care, where usual care by the GP or sports physi-
cian was compared with referral to a podiatrist for 
a custom- made insole and to referral to a podiatrist 
for a sham insole, with a follow- up of 6 months. 
Participants provided informed consent.
Participants
A total of 175 GPs and 6 sports physicians were 
engaged in the study and invited patients with 
plantar heel pain to participate in the study. Inclu-
sion criteria for study participation were: age 
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between 18 to 65 years, minimal pain duration of 2 weeks and 
presentation with plantar heel pain, characterised as pain at the 
medial hind foot. Exclusion criteria were: recurrent complaints 
of plantar heel pain for more than 2 years, complaints caused 
by trauma, earlier treatment for plantar heel pain by a podia-
trist or with insoles, suspected (by the GP or sports physician) 
osteoarthritis in the subtalar or talonavicular joint, suspected 
tarsal tunnel syndrome, suspected stress fractures, infections or 
tumours in the painful foot, presence of systemic diseases (such 
as ankylosing spondylitis, psoriasis or multiple sclerosis) and 
insufficient understanding of the Dutch language. Patients who 
were regarded eligible by the GP or sports physician and were 
interested in the study were double screened on eligibility by the 
research assistant by telephone.
Randomisation and blinding
Participants were randomised with the use of a computer- 
generated randomisation list using block randomisation with 
random block sizes between 3 and 10 with a 2:3:3 allocation 
randomisation ratio, to receive the following interventions:
 ► Referral to podiatrist for custom- made insole (custom- made 
insole).
 ► Referral to podiatrist for sham insole (sham).
 ► GP- led usual care (usual care).
The randomisation list was created by an independent person 
(data manager) and the sequence was hidden from all involved 
researchers. Randomisation was stratified for type of referral 
(GP or sports physician). Patients were blinded to the type of 
insole they received. Podiatrists were blinded during the first 
consultation, but received information necessary to fabricate the 
insole after the first consultation and were no longer blinded 
afterwards. Podiatrists were instructed to not inform the patients 
about the allocation during the course of the study. GPs remained 
blinded as well as they did not receive any information on group 
allocation.
Interventions
Participants allocated to the usual care group received usual care 
by their GP or sports physician. This included a non- surgical 
approach and any intervention the physician considered to 
be necessary for each particular patient, except a referral to a 
podiatrist.
Participants allocated to the custom- made insole group and 
the sham insole group, were referred to one of the 50 partic-
ipating podiatrists. In the Netherlands, a podiatrist is a certi-
fied paramedical specialist providing podiatric care. Participants 
referred to a podiatrist received a standardised assessment, 
including the making of a 3D (three- dimensional) imprint of the 
feet of the patient. After this intake, the podiatrist contacted the 
research team to receive the allocation of the patient. Conse-
quently, participants randomised to the custom- made insole 
group received a custom- made insole, which was manufactured 
at the discretion of the individual podiatrist. Therefore, multiple 
approaches were used. The common goal was to influence the 
biomechanical process to reduce traction on the plantar aponeu-
rosis and to reduce ground reaction force below the calcaneal 
tuberosity. To achieve this, most applied full- length insoles with 
shock absorbing material (PPT/Poron of 15 Shore A) at the 
calcaneus, with or without a shell shape under the attachment 
of the medial portion of the plantar aponeurosis. A corrective 
element for the calcaneus aimed to correct range of motion of 
the tarsus in frontal plane and often an additional arch support 
was applied. The material used for the insoles was of 30 to 
60 Shore A. Participants randomised to the sham insole group 
received a sham insole that was designed for each participant 
(based on the 3D imprint) and designed to have the visual effect 
of a podiatric insole, but providing as little mechanical effect as 
possible. All sham insoles were produced by the same podiatrist 
after receiving the 3D imprint from the different podiatrists. The 
sham insoles were sent back to the different podiatrists to give to 
the patients. The detailed procedure for making the sham insole 
is described elsewhere.14 The procedures on the standardised 
assessment, the allocation concealment and the manufacturing 
of the custom and sham insole were agreed on in a consensus 
meeting with participating podiatrists.
Participants in all three groups received an information 
booklet with general information on plantar heel pain, as well as 
information on stretching and strengthening exercises, based on 
those described by Digiovanni et al and Rathleff et al9 15
Podiatrists were instructed to provide patients with the allo-
cated insole and to provide exercises and shoe advice when 
needed and to withhold other interventions available to them. 
Physicians were instructed not to refer patients in the usual care 
group to a podiatrist during the study period. Other interven-
tions, including the prescription of paracetamol or non- steroidal 
anti- inflammatory drugs, as well as all other co- interventions, 
were left to the physician’s decision.
Outcomes
Participants completed online questionnaires at baseline, 2, 4, 
6, 12 and 26 weeks of follow- up. At baseline, information on 
demographics including the activity score (in tertiles) based 
on the SQUASH questionnaire (ShortQuestionnaire to Assess 
Health- enhancing Physical Activity) was gathered.16 The primary 
outcomes were the differences in pain at rest and during activity 
on a 11- point Numerical Rating Scale (NRS) at the 12- week 
follow- up between the custom insole group and sham group, 
and compared with usual care.17 Secondary outcomes included, 
first step pain, the Foot Function Index (FFI 0 to 100) and the 
self- reported recovery on a 7- point Likert scale after 12 weeks 
follow- up.18 19 Pain, recovery and foot function were measured 
at all time points. Quality of life according to SF12 (The12- Item 
Short Form Health Survey) was measured at baseline, 12 weeks 
and 26 weeks of follow- up.20 The 26- week follow- up question-
naire additionally included items on compliance, patient satis-
faction and success of blinding. For participants allocated to 
an insole, the podiatrist reported whether they agreed with the 
referral based on their findings at the baseline assessment.
Statistical analysis and sample size
Sample size was based on the ability to detect a clinically relevant 
effect size of 0.5, translated to a difference in pain score of 10.5 
(SD 21.5, based on Landorf et al) on a scale of 0 to 100 between 
patients with a sham insole and custom- made insole at the 12- week 
follow- up.21 22 The sample size of the usual care group was based 
on the expected larger difference (12 points on 0 to 100 scale) 
between usual care and custom- made insole, as described in the 
protocol.14 Differences between the insole groups were analysed 
following the intention- to- treat principle. For the continuous 
outcomes linear mixed models with repeated measures were used 
to compare the intervention group and control groups and results 
expressed in mean differences (MD). To model the covariance of 
repeated measures by patients, the option for data structure in the 
analyses was set on ‘Unstructured’, because this had the lowest 
Akaike’s information criterion. Fixed effects were time and time 
by treatment. All time measures of the outcome taken before the 
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outcome of interest (including baseline values) were included in 
the analyses. For the outcome self- reported recovery at 6, 12 and 
26 weeks, generalised linear models (with a logit link and binomial 
distribution) were used and results expressed in relative risks (RR). 
Missing data were handled with restricted maximum likelihood 
which generates unbiassed estimates of the population covariance 
parameters and does not reject cases where one or more data items 
are missing. For self- reported recovery, the number needed to treat 
is presented (defined as 1/absolute relative risk) and for continuous 
data, effect sizes (Hedges g) with accompanied CIs were calculated.
A Bonferroni correction was performed for the secondary 
comparisons to the usual care group. The analyses were adjusted 
for potential confounders at least including age, sex, BMI and 
activity level and variables that changed the effect estimate of 
the outcome of interest by >10%. Potential confounders were 
tested for collinearity. Predefined subgroup analysis as described 
in the protocol were performed.14 All analyses were performed 
with IBM SPSS Statistics (V.25).
RESULTS
Participants
Inclusion lasted from September 2015 until May 2018 with 
the last follow- up being conducted in November 2018. Three 
hundred and eighteen patients were interested in the study after 
being informed by their GP. Of these, 185 participants were 
eligible and included: 70 in the custom- made insole group, 69 
in the sham insole group and 46 in the usual care group. The 
flow of patients is presented in figure 1. All 185 participants 
were referred to the study by their GP, there were no referrals by 
sports physicians. Baseline demographics and characteristics are 
reported in table 1.
Figure 1 Flowchart depicting the flow of patients in the STAP- study.
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Primary and secondary outcomes
No differences were seen between the custom- made insole and 
the sham insole group in pain and function at 12 weeks (table 2). 
The 95% CIs of this comparison exclude any relevant favour-
able effect of the custom- made insole. After 12 weeks, the group 
randomised to GP- led usual care showed significantly larger 
improvements compared with the group randomised to custom 
insoles in pain during activity (mean difference (MD) 0.94, 
95% CI 0.23 to 1.65), first step pain (MD 1.48, 95% CI 0.65 to 
2.31), FFI pain subscale (MD 6.27, 95% CI 0.84 to 11.69), FFI 
function subscale (7.37, 95% CI 1.27 to 13.46) and self- reported 
recovery (RR 0.48, 95% CI 0.24 to 0.96). The differences were 
small compared with the known minimal clinical differences; 
only the FFI function subscale exceeded the minimal clinical 
important difference of 7.21 23
Co-interventions and compliance
Reported co- interventions up to 12 weeks follow- up are 
presented in table 3. Patients allocated to usual care reported 
more visits to the GP (46.2% vs 27.3%, respectively), more use 
of heel cups or other biomechanical interventions (41.0% vs 
22.7%, respectively) and received a corticosteroid injection more 












Mean (SD) unless 
otherwise indicated
Mean (SD) unless 
otherwise indicated
Mean (SD) unless 
otherwise indicated
Mean (SD) unless 
otherwise indicated
Age, y 47.6 (10.6) 48.0 (11.3) 48.2 (9.4) 46.1 (11.4)
Sex, female, No (%) 128 (69.2) 48 (68.6) 48 (69.6) 32 (69.6)
Educational level, No (%)
Low 59 (31.9) 23 (32.9) 20 (29.0) 16 (34.8)
Middle 86 (46.5) 29 (41.4) 33 (47.8) 24 (52.2)
High 40 (21.6) 18 (25.7) 16 (23.2) 6 (13.0)
BMI 29.7 (5.3) 29.2 (5.8) 29.5 (4.8) 30.9 (5.0)
Pain history
  Localization of complaints, bilateral, No (%) 45 (24.3) 16 (22.9) 16 (23.2) 13 (28.3)
  Duration of pain, mo 6.2 (10.4) 7.7 (15.5) 5.1 (5.2) 5.4 (5.6)
  VAS during rest (0–10) 4.1 (2.6) 3.8 (2.5) 4.0 (2.7) 4.9 (2.4)
  VAS during activity (0–10) 6.8 (2.0) 6.8 (2.0) 6.7 (2.1) 7.0 (1.8)
  VAS first step pain (0–10) 7.2 (2.3) 7.2 (2.4) 7.3 (2.1) 7.2 (2.5)
  DN4 (0–10>4indicates neuropathic pain) 3.7 (2.1) 3.9 (2.1) 3.6 (1.8) 3.7 (2.3)
  FFI total (0–100) 48.7 (18.0) 50.2 (18.8) 46.1 (17.2) 50.3 (18.0)
  FFI disability (0–100) 39.6 (20.9) 41.6 (23.1) 37.3 (19.7) 40.1 (19.3)
  FFI pain (0–100) 58.7 (17.7) 60.0 (16.7) 55.6 (17.2) 61.2 (19.6)
  FPDI function (9-27) 17.5 (4.4) 17.2 (4.2) 17.6 (4.9) 17.9 (4.2)
  Self- reported illness in the past 12 months, No (%) 116 (62.7) 45 (64.3) 45 (65.2) 26 (56.5)
  Other musculoskeletal pain at baseline, No (%) 78 (42.2) 29 (41.4) 32 (46.4) 17 (37.0)
Quality of life
  SF12 Physical health (0–100) 38.2 (8.4) 39.0 (8.4) 37.9 (8.7) 37.4 (7.8)
  SF12 Mental health (0–100)* 49.2 (10.1) 46.9 (11.1)* 51.2 (8.9)* 49.5 (9.9)
  EQ- 5D Utility score (0–1) 0.7 (0.2) 0.7 (0.3) 0.7 (0.2) 0.7 (0.2)
Activity level
  SQUASH 7716.7 (5270.0) 6761.3 (4525.5) 8755.3 (5747.8) 7612.6 (5398.8)
Self- reported interventions for PHP in the 3 months prior to inclusion
  Visit to GP, No (%) 165 (89.2) 60 (85.7) 62 (89.9) 43 (93.5)
  Visit to physiotherapist, No (%) 15 (8.1) 6 (8.6) 5 (7.2) 4 (8.7)
  Use of pain medication, No (%) 73 (39.5) 30 (42.9) 25 (36.2) 18 (39.1)
  Exercises, No (%) 73 (39.5) 26 (37.1) 29 (42.0) 18 (39.1)
  Shockwave, No (%) 2 (1.1) 2 (2.9) – –
  Dry Needling, No (%) 1 (0.5) – 1 (1.4) –
  Massage/ manipulation, No (%) 4 (2.2) 1 (1.4) 3 (4.3) –
  Custom insoles, No (%) 1 (0.5) 1 (1.4) – –
  Prefabricated orthotic, No (%) 67 (36.2) 29 (41.4) 25 (36.2) 13 (28.3)
  Shoe advice, No (%) 14 (7.6) 4 (5.7) 8 (11.6) 2 (4.3)
  Corticosteroid injection, No (%) 3 (1.6) – 2 (2.9) 1 (2.2)
*There was a mean difference of 4.28 (95% CI 0.18 to 8.38) on the mental health component of the SF12 between the sham insole group and the custom- made insole group, in 
favour of sham insole.
BMI, body mass index; DN4, Douleur Neuropathique 4; EQ- 5D, EuroQol five dimension scale; FFI, Foot Function Index (total score and pain and disability subscales); FPDI, 
(Manchester) Foot Pain and Disability Index (function subscale); mo, months; No, number of participants; SF12, The 12- Item Short Form Health Survey; SQUASH, Short 
Questionnaire to Assess Health- enhancing Physical Activity; VAS, Visual Analogue Scale; y, years.
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often (15.4% vs 0%, respectively) compared with both insole 
groups. Newly reported co- interventions at 26 weeks, that were 
not reported at 12 weeks, are presented in online supplementary 
file 1. One hundred and eighteen patients that were allocated to 
an insole intervention completed questions on their compliance 
and satisfaction at 26 weeks of follow- up. Of these, 68 (57.6%) 
reported wearing their insoles every day (51.7% in the custom- 
made insole group vs 63.3% in the sham insole group), 10 
patients (8.4%; 5 patients in each group) reported never wearing 
them and 40 patients (33.6%; 39.6% in the custom- made insole 
group and 28.3% in the sham insole group) reported wearing 
their insoles sometimes, with no differences between groups. 
Blinding appeared to be successful as shown in table 4.
For 131 participants allocated to an insole, the podiatrist 
reported the agreement with the referral. In 96.2% of these partic-
ipants they agreed with the indication for insoles, in the other 
five cases the podiatrist indicated that normally they would have 
chosen another type of treatment. Negative effects of the insoles in 
our study included discomfort when wearing the insoles (reported 
by 31 participants: 8 in sham group and 23 in insole group) and an 
increase in pain when wearing the insole (reported by 22 partici-
pants; 7 in sham group and 15 in insole group).
Predefined subgroup analyses
Predefined subgroup analyses were performed on participants with 
a duration of complaints <12 months at baseline (n=160), partic-
ipants in which the podiatrist agreed with the referral (n=180) 
and patients with a high or intermediate activity (in tertiles) based 
on the SQUASH (n=124). These results are presented in online 
supplemental file 2. Among participants with short duration of 
complaints, the differences in pain during activity between the 
insole and the usual care group were no longer significant, but the 
size and direction of effect were similar.
Patient and public involvement
No patients were involved in the planning and development of 
this study. The results will be disseminated directly to all partic-
ipants via email.
DISCUSSION
This study found no differences between a custom- made insole 
and a sham insole on pain, function, recovery or quality of life 
in patients with plantar heel pain. Patients with plantar heel pain 
treated with GP- led usual care experienced less pain, better func-
tion and greater improvement compared with patients allocated 
to the custom- made insole intervention. However, the differences 
found were small and did not reach clinical importance except for 
foot function.21 23 In the subgroup analysis for participants with 
a relatively short duration of complaints, the differences in pain 
during activity between the custom- made insole and the usual 
care group were no longer significant. The direction of effect was 
however comparable.
Comparison with existing literature
To our knowledge, this is the first randomised trial that compares 
the effectiveness between two commonly used treatment 
approaches: GP- led usual care versus referral to a podiatrist for 
custom- made insoles. Our results show no superiority of a custom- 
made insole over a sham insole and over usual care. Two systematic 
reviews found conflicting evidence for the effectiveness of custom- 
made insoles.12 13 A randomised controlled trial (RCT) published 
after these reviews, found a significant effect on first step pain in 
favour of custom- made insoles in new shoes versus sham insole 
in the patients regular shoes.24 The most recent systematic review 
comparing different treatment options for plantar heel pain found 
that none of the commonly used treatments (including orthoses) 
were better than the other and that data on long- term effects was 
Table 3 Co- interventions reported at 12 weeks follow- up
Intervention
12 weeks
Custom- made insole (n, %) (n=66)* Sham insole (n, %) (n=68)* Usual care (n, %) (n=39)* P value
Consulted with healthcare practitioner†   
  General practitioner 18 (27.3) 16 (23.5) 18 (46.2) 0.04
  Specialist 1 (1.5) 3 (4.4) – 0.30
  Physiotherapist 6 (9.1) 7 (10.3) 5 (12.8) 0.83
  Other healthcare provider (ex. acupuncturist) 1 (1.5) 2 (1.5) – 0.53
Interventions   
  Pain medication 18 (27.3) 21 (30.9) 15 (38.5) 0.49
  Exercises 42 (63.6) 45 (66.2) 21 (53.8) 0.43
  Shockwave – 2 (2.9) 2 (5.1) 0.22
  Dry needling 1 (1.5) 2 (2.9) – 0.53
  Massage/manipulation 4 (6.1) – 2 (5.1) 0.13
  Other biomechanical interventions‡ 15 (22.7) 9 (13.2) 16 (41.0) <0.001
  Shoe advice 11 (16.7) 7 (10.3) 7 (17.9) 0.44
  Corticosteroid injection – – 6 (15.4) <0.001
*The N is given for the number of patients that has completed the part of the questionnaire regarding co- interventions. Values are numbers (percentages) unless stated 
otherwise
†Contacts do not include those as part of trial interventions or those mentioned as cross- over in the flowchart.
‡Other biomechanical interventions included prefabricated insoles, heel cups, night splints or Strasbourg socks, supportive stockings or tape.
Table 4 Answers to question regarding blinding, asked at 26 weeks 
follow- up to patients allocated to either sham or insole
Answer to question: ‘Which intervention 
do you think you received?’ Asked at 26 
weeks follow- up to patients that were 
allocated to either sham or insole
Allocated to custom- 





Sham 12 (17.1%) 13 (18.8%)
Insole 20 (28.6%) 21 (30.4%)
Don’t know 26 (37.1%) 26 (37.7%)
No answer 12 (17.1%) 9 (13.0%)
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lacking.25 So the findings of our study align with the most recent 
systematic review synthesis, including 20 RCTs on efficacy of foot 
orthoses. No previous randomised trials included a usual care 
treatment strategy in primary care.
Strengths and limitations
This study adds to literature, since it provides a comparison of 
custom- made insoles and usual care of the GP in patients with 
plantar heel pain. Usual care in our study consisted of the care 
that the GP would normally provide for these patients and all 
participants additionally received an information booklet with 
exercises. Participants in the usual care group reported more visits 
to the GP and more use of freely available biomechanical inter-
ventions and corticosteroid injection as co- interventions at 12 
weeks. Biomechanical interventions such as heel cups, and corti-
costeroid injections are common interventions by GPs.8 Since the 
use of biomechanical interventions was questioned by a single 
yes- no question, we do not have specific information on the time 
that these interventions were used. It is possible that this affected 
the results. The use of pain medication (apart from corticoste-
roid injection) was comparable between groups throughout the 
entire study. However, the GPs may have applied more interven-
tions, that is, corticosteroid injections, pain medication and other 
biomechanical interventions to patients in the usual care group in 
this trial than what is reflective for usual care (less corticosteroid 
injections (1.4%) and less pain medication (19.9%)) .7 This may 
have influenced the treatment effects of usual care in this trial. An 
additional subgroup analysis excluding the six patients who had 
received a corticosteroid injection found a comparable MD as the 
main analysis. This subgroup analysis may be biassed since patients 
who received a corticosteroid injection seemed to have more 
severe complaints at baseline. The GP- led usual care group had 
access to more co- interventions, which might have enhanced the 
treatment effects in this group. The co- interventions were compa-
rable between the custom made insole group and the sham insole 
group.
Information on adherence to the podiatry- led interventions was 
only collected at 26 weeks of follow- up and may be influenced by 
recall bias.
The sham insoles may have mechanical effects on the foot, and 
blinding might be an issue.26 27 The sham intervention used in 
this study was especially designed by podiatrists to minimise any 
mechanical effect, but this cannot be ruled out. Neither were any 
biomechanical tests applied to test these possible effects. We did 
observe successful blinding of the patients (table 4).
No patients were included by participating sports physicians. The 
study results might therefore not be generalisable to a population 
with a high activity level. Moreover, the inclusion of patients was 
based on the clinical diagnosis by the GP and we did not include 
the specific criteria of pain at palpation of the medial tubercle of 
the calcaneus, as in prior RCTs of plantar heel pain.28 29
One of our primary outcomes was pain at rest. We did not find 
any differences between the groups for this outcome at any time 
point, in contrast to pain during activity and first step pain. Scores 
for pain at rest were relatively low at baseline, which might reflect 
that walking after a period of inactivity is most burdensome for 
patients with plantar heel pain. Pain at rest may not be an appro-
priate outcome for patients with plantar heel pain.
Implications for research and practice
Since this is the first RCT in patients with plantar heel pain using 
usual care by the GP as a treatment arm, more studies on plantar 
heel pain including a comparison of usual care (GP- led or other) 
or watchful waiting are needed. When communicating to patients 
and clinicians about usual care, it is important to explain that this 
is not the same as doing nothing. Exercise- therapy and general 
advice should be included in these approaches. Taking the results 
of this study into account, GPs can apply a usual care approach, 
including different types of interventions, when treating plantar 
heel pain. Since custom- made insoles do not have an additional 
beneficial effect over sham insoles and GP- led usual care, health-
care providers should be reserved in prescribing custom- made 
insoles to patients with plantar heel pain.
Summary box
What are the findings?
 ► In patients with plantar heel pain in general practice, 
treatment with custom- made insoles does not have 
additional value compared with the usual care provided by 
the general practitioner.
 ► No differences were found between custom- made insole and 
sham insole treated patients with plantar heel pain.
How might it impact on clinical practice in the future?
 ► Healthcare providers such as GP’s and podiatrists should be 
reserved in prescribing custom- made insoles to patients with 
plantar heel pain.
Twitter Marienke van Middelkoop @mvanmiddelkoop
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